MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ejh.13949

Медицинская библиотека · European journal of haematology · 2023

Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.

Leebeek Frank W G, Peyvandi Flora, Tiede Andreas, Castaman Giancarlo, Escobar Miguel, Wang Michael, Zülfikar Bulent, Susen Sophie, Miesbach Wolfgang, Wang Scarlett, Wang Yi, Zhang Jingmei, Özen Gülden

Клиническое исследование III фазыСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To describe efficacy/safety of recombinant von Willebrand factor (rVWF) prophylaxis in patients with type 3 von Willebrand disease (VWD).

METHODS

This post hoc analysis of a phase 3 open-label trial provides a more detailed analysis of adults with type 3 VWD, categorized based on prior treatment at screening: "Prior On-Demand (OD)" (OD VWF; ≥3 documented spontaneous bleeding events [BEs] requiring VWF in previous 12 months) or "Switch" (plasma-derived [pd] VWF prophylaxis for ≥12 months). Annualized bleeding rates (ABRs) were evaluated during 12 months of rVWF prophylaxis versus historical data from medical records.

RESULTS

In the Prior OD group (n = 10), mean spontaneous ABR (sABR) for treated BEs was reduced by 91.6% (ratio, 0.08; 95% CI, 0.02-0.45) versus mean historical sABR. In the Switch group (n = 8), mean sABR for treated BEs was reduced by 47% (ratio, 0.53; 95% CI, 0.08-3.62). One non-serious adverse event (AE) was considered possibly related to rVWF. No treatment-related, fatal, or life-threatening serious AEs were reported, and no patient developed VWF inhibitors.

CONCLUSIONS

rVWF prophylaxis reduced sABR in type 3 VWD patients previously treated with OD VWF therapy, and maintained a similar level of hemostatic control in those switching from pdVWF prophylaxis to rVWF prophylaxis.

Для цитирования: Leebeek Frank W G, Peyvandi Flora, Tiede Andreas, Castaman Giancarlo, Escobar Miguel, Wang Michael, Zülfikar Bulent, Susen Sophie, Miesbach Wolfgang, Wang Scarlett, Wang Yi, Zhang Jingmei, Özen Gülden. Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.. European journal of haematology. 2023. DOI: 10.1111/ejh.13949.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.